Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Out-licensing
- View
Transdermal narcotic analgesic therapy (Fentanyl and buprenorphine)
Fentanyl and Buprenorphine are indicated for the management of severe pain in patients who require continuous opioid analgesia
Mechanism of action
Systemic
Full description
Indicated for chronic and intractable pain, Amarin develops
fentanyl TDS and buprenorphine, transdermal narcotic
analgesic therapies formulated as drug-in-adhesive patches.
Fentanyl TDS is indicated for chronic and intractable pain;
this product was recently launched in Argentina. Presently,
Fentanyl TDS is under registration in other countries of
South America and Europe.
Buprenorphine TDS is indicated for chronic severe disabling
pain not responding to non-narcotic analgesics. This patch
is under development (feasibility studies).
Development status
Preregistration
Patent information
Two International Patent Applications were filed 2003. In
2004 re-validations were submitted in USA, Europe, Mexico and
India.
Type of business relationship sought
Amarin is willing to consider a range of partnership options
for these TDS patches.
Licensing contact
Mr. Sergio Lucero
Managing Director
Managing Director
More information
For more information about the product please visit website.
Company details
Amarin Technologies S.A.
Amarin is engaged in the development of innovative pharmaceutical products using its proprietary topical and transdermal drug delivery technologies and know-how.
Amarin is engaged in the development of innovative pharmaceutical products using its proprietary topical and transdermal drug delivery technologies and know-how.
Related reports
Are you looking for reports related to this particular subject. Our Reports section is the best place to start.
Related items
- Cellophil(TM) Biomedical Polymer - New and superior biomedical polymers for a new standard in the medical device industry.
- Transdermal Diclofenac
- Sulidin® nimesulide LPS Non-Steroidal Topical Anti-inflammatory gel for the local treatment of painful inflammatory conditions.
- Ropinirole (Requip) for a fibromylagia indication
- Diffucaps® Sodium Diclofenac SR capsules 75 and 150mg
Related categories
- Industry sector
- Drug delivery
- Drug delivery / Systemic
- Drug delivery / Systemic / Transdermal system
- Pharmaceutical
- Pharmaceutical / Generics
- Pharmaceutical / Prescription
- Therapeutic target
- Central Nervous System
- Central Nervous System / Pain / Pain, post-operative
- Central Nervous System / Pain / Pain, neuropathic
- Central Nervous System / Pain / Pain, inflammatory
- Central Nervous System / Pain / Pain, chronic
- Central Nervous System / Pain / Pain, cancer
- Central Nervous System / Pain / Pain, back upper/lower
- Central Nervous System / Pain / Pain, AIDS-related
- Central Nervous System / Pain / Pain, acute
- Oncology
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us